加载中
NASDAQHealthcareBiotechnology
最新数据
US$54.54
−US$2.38 · -4.18%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
前收盘价
US$54.54
−US$2.38 · -4.18%
盘前
US$54.00
−US$0.54 · -0.99%
10月8日 7:22 ET
盘中时间采用ET。市场数据可能有所延迟。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日内区间
当前US$54.54
52周区间
当前US$54.54
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
40
偏贵
情绪
55
多空交织
风险
39
中等风险
动量
81
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日内区间
当前US$54.54
52周区间
当前US$54.54
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 销货成本 | 24.8万 USD | — | — | — |
| 毛利 | −24.8万 USD | — | — | — |
| 研究与开发 | 7915.9万 USD | 5741.5万 USD | 2853.4万 USD | 2139.7万 USD |
| 销售、一般及管理费用 | 1889.6万 USD | 1077.9万 USD | 677.7万 USD | 376.4万 USD |
| 营业费用 | 9805.5万 USD | 6819.4万 USD | 3531.1万 USD | 2516.1万 USD |
| 利息收入 | 1108.4万 USD | 627.2万 USD | 274.8万 USD | 37.2万 USD |
| 利息支出 | — | — | — | 37.4万 USD |
| 折旧和摊销 | 24.8万 USD | 24.4万 USD | 15.7万 USD | 5.6万 USD |
| 营业利润 | −9805.5万 USD | −6819.4万 USD | −3531.1万 USD | −2516.1万 USD |
| 净利润 | −8697.1万 USD | −6192.2万 USD | −3256.3万 USD | −2613.5万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7011.74万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM4623.2万0.06%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF1903.69万0.02%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO1656.02万0.12%142.49亿 USD0.24%US$355.37-1.43%
iShares Biotechnology ETFIBB1313.51万0.13%104.01亿 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO1099.18万0.06%180亿 USD0.06%US$112.21-1.26%
State Street SPDR S&P Pharmaceuticals ETFXPH906.83万1.86%4.62亿 USD0.35%US$62.910.00%
Schwab U.S. Small-Cap ETFSCHA884.02万0.04%216.99亿 USD0.03%US$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
